

Formulary Update

September 2022

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since July 2022. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Methadone	No longer first line choice in Preferred List for opioid dependence	4.10.3	Scottish MTA Standards, GGC formulary appeal
Buprenorphine MR injection	Now in Preferred List (rather than Total Formulary) for opioid dependence	4.10.3	Scottish MTA Standards, GGC formulary appeal
Buprenorphine oral lyophilisate	Now in Preferred List (rather than Total Formulary) for opioid dependence	4.10.3	Scottish MTA Standards, GGC formulary appeal